Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Cash & Equivalents (2021 - 2026)

Nuvectis Pharma has reported Cash & Equivalents over the past 6 years, most recently at $25.1 million for Q1 2026.

  • Quarterly results put Cash & Equivalents at $25.1 million for Q1 2026, down 16.05% from a year ago — trailing twelve months through Mar 2026 was $25.1 million (down 16.05% YoY), and the annual figure for FY2025 was $31.6 million, changed.
  • Cash & Equivalents reached $25.1 million in Q1 2026 per NVCT's latest filing, down from $31.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $35.4 million in Q3 2025 and bottomed at $13.6 million in Q2 2022.
  • Median Cash & Equivalents over the past 5 years was $22.9 million (2022), compared with a mean of $22.8 million.
  • The largest annual shift saw Cash & Equivalents fell 26.36% in 2024 before it skyrocketed 106.43% in 2025.
  • Over 5 years, Cash & Equivalents stood at $23.6 million in 2022, then fell by 6.51% to $22.1 million in 2023, then decreased by 22.31% to $17.2 million in 2024, then surged by 84.25% to $31.6 million in 2025, then decreased by 20.65% to $25.1 million in 2026.
  • Business Quant data shows Cash & Equivalents for NVCT at $25.1 million in Q1 2026, $31.6 million in Q4 2025, and $35.4 million in Q3 2025.